Last reviewed · How we verify

cART(TDF/AZT+3TC+LPV/r)

Yongtao Sun, MD, PhD · Phase 3 active Small molecule

cART(TDF/AZT+3TC+LPV/r) is a combination antiretroviral therapy that works by inhibiting the replication of HIV.

cART(TDF/AZT+3TC+LPV/r) is a combination antiretroviral therapy that works by inhibiting the replication of HIV. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV.

At a glance

Generic namecART(TDF/AZT+3TC+LPV/r)
Also known asTenofovir Disoproxil Fumarate, Zidovudine, Lamivudine, Lopinavir/ritonavir (Kaletra)
SponsorYongtao Sun, MD, PhD
Drug classNucleoside reverse transcriptase inhibitor, Protease inhibitor, Nucleotide reverse transcriptase inhibitor
TargetHIV reverse transcriptase, HIV protease
ModalitySmall molecule
Therapeutic areaInfectious Diseases
PhasePhase 3

Mechanism of action

This combination therapy includes tenofovir disoproxil fumarate (TDF), a nucleotide reverse transcriptase inhibitor; zidovudine (AZT), a nucleoside reverse transcriptase inhibitor; lamivudine (3TC), a nucleoside reverse transcriptase inhibitor; and lopinavir/ritonavir (LPV/r), a protease inhibitor. By targeting multiple stages of the HIV life cycle, this combination therapy aims to suppress viral replication and reduce the risk of transmission and disease progression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: